MK-2206
200px | |
Names | |
---|---|
IUPAC name
8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one
|
|
Identifiers | |
ChemSpider | 24658140 |
Jmol 3D model | Interactive image |
PubChem | 24964624 |
|
|
|
|
Properties | |
C25H21N5O | |
Molar mass | 407.48 g·mol−1 |
Vapor pressure | {{{value}}} |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
Infobox references | |
MK-2206 is a drug candidate being investigated to help treat cancer. Its chemical formula is C25H21N5O.[1] It acts as an allosteric AKT inhibitor.[2]
It is a highly selective inhibitor of pan-Akt, namely, of all three Akt isoforms Akt1, Akt2, and Akt3.[1]
It is intended to be used with other cancer therapies that advanced tumours may become resistant to.[3]
Clinical trials
2011: A phase 1 clinical trial of MK-2206 alone has reported it was well tolerated.[4]
2014: A phase 1 clinical trial of MK-2206 with a variety of other agents in 72 patients with advanced cancer reported acceptable side-effects.[3]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
<templatestyles src="Asbox/styles.css"></templatestyles>
- ↑ 1.0 1.1 MK-2206 dihydrochloride (CAS 1032350-13-2) inc structure diagram
- ↑ MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo. Hirai et al. 2010
- ↑ 3.0 3.1 A trial of MK-2206 with chemotherapy or erlotinib for advanced cancer
- ↑ First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
- Pages with reference errors
- Pages with broken file links
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Articles without KEGG source
- Articles without UNII source
- Pages using collapsible list with both background and text-align in titlestyle
- Articles containing unverified chemical infoboxes
- Pharmacology stubs
- Protein kinase inhibitors
- Experimental cancer drugs